Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2328 - Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)


10 Oct 2016


Poster display


Gabriel Rinnerthaler


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


G. Rinnerthaler1, S.P. Gampenrieder1, D. Voskova2, A. Petzer3, M. Hubalek4, E. Petru5, B. Hartmann6, J. Andel7, M. Balic8, T. Melchardt1, B. Mlineritsch1, R. Greil1

Author affiliations

  • 1 Iiird Medical Department, Salzburg Cancer Research Institute With Laboratory Of Immunological And Molecular Cancer Research And Center For Clinical Cancer And Immunology Trials, Cancer Cluster Salzburg, Paracelsus University Hospital Salzburg, 5020 - Salzburg/AT
  • 2 3rd Medical Department, Kepler University Hospital, 4020 - Linz/AT
  • 3 Internal Department I For Medical Oncology And Hematology, Barmherzige Schwestern Hospital Linz, 4010 - Linz/AT
  • 4 Department Of Obstetrics And Gynaecology, Innsbruck Medical University, 6020 - Innsbruck/AT
  • 5 Department Of Obstetrics And Gynaecology, Medical University Graz, 8036 - Graz/AT
  • 6 Medical Department E, General Hospital Feldkirch, 6807 - Feldkirch/AT
  • 7 2nd Medical Department, County Hospital Steyr, 4400 - Steyr/AT
  • 8 Division Of Oncology, Medical University Graz, 8036 - Graz/AT


Abstract 2328


Capecitabine is a well-established treatment option in HER2-negative advanced breast cancer (ABC) patients. Bendamustine is a generally well tolerated cytotoxic drug. Since bendamustine has already shown anticancer activity in ABC we evaluated the efficacy and tolerability of bendamustine in combination with capecitabine in 40 pretreated patients with ABC.


MBC-6 is a non-randomized, multicenter, open-label, single-arm phase II study in patients with HER2-negative ABC (ClinicalTrials.gov identifier: NCT01891227). All patients were pretreated with anthracyclines and/or taxans and measurable disease according to RECIST 1.1. had to be present at baseline. Eligible patients received 1000 mg/m2 capecitabine twice daily on days 1 to 14 in combination with 80 mg/m2 bendamustine on day 1 and 8 of a 3-week cycle. After a maximum of eight cycles, capecitabine was continued as single drug therapy until disease progression or unacceptable toxicity. Efficacy results have been presented at the ASCO Annual Meeting 2016, Abstr 1032. Here we report the updated safety analysis.


From September 2013 to May 2015, 40 patients were recruited in 8 Austrian centers. At data cut-off on 05/02/16 overall 37 of 40 patients had discontinued treatment: 25 (68%) due to progressive disease, 4 (11%) because of adverse events (AEs), 7 (18%) on their own or investigator decision and 1 (3%) due to protocol violation. Twelve patients (30%) experienced at least one drug related non-hematological AE ≥ grade 3 during combination treatment (2 infections, 1 erysipelas, 5 fatigue, 4 thromboembolic events, 2 diarrhea, 1 nausea, 1 emesis, 1 constipation, 1 syncope, 1 polyneuropathy, 1 stomatitis, 1 hand-foot syndrome, each grade 3) and further 6 patients (15%) during capecitabine maintainance (3 infections, 3 diarrhea, and 4 hand-foot syndroms, each grade 3). Three grade 4 hematological AEs (neutropenias) were observed. One patient died as a result of restrictive cardiomyopathy, where a relationship to capecitabine cannot be excluded, but seems unlikely.


The combination of capecitabine and bendamustine has a moderate toxicity profile. Final study results are awaited later in 2016.

Clinical trial identification

ClinicalTrials.gov identifier: NCT01891227

Legal entity responsible for the study

AGMT (Arbeitsgemeinschaft medikamentöse Tumortherapie - Study Group of Medical Tumour Therapy) Wolfsgartenweg 31 5026 Salzburg, Austria


This research was supported in part by a Research Grant from Mundipharma®


A. Petzer: Conflicts of Interest with Mundipharma®: Fees for non-CME services received directly from commercial interest or their agents and Traveler Grants. E. Petru, R. Greil: Conflicts of Interest with Mundipharma®: Fees for non-CME services received directly from commercial interest or their agents.

J. Andel: Conflicts of Interest with Mundipharma®: Consultant or Advisory Role. M. Balic: Conflicts of Interest with Mundipharma®: Consultant or Advisory Role and Traveler Grants. B. Mlineritsch: Conflicts of Interest with Mundipharma®: Consultant or Advisory Role, and Fees for non-CME services received directly from commercial interest or their agents. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings